
dec pm et
summari compani leader pharmaceut medic devic consum product
nm price-to-earnings oper ep
risk assess reflect benefit
product larg immun econom cycl
reli singl product categori
sustain growth enjoy competit
advantag owe substanti financi resourc
divers product offer global sale capabl
strength balanc somewhat
unpredict natur drug patent challeng
pipelin well advers legal rule
brought health care product develop
case also damag brand associ
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
dec stock trade
jnj sale grew yoy led pharma
sale growth oncolog
drug strongest perform increas
sale yoy
approxim entir compani total
revenu increas quarter expect
pharma continu drive growth
especi stelara imbruvica
darzalex increas sale
yoy help improv pharma
margin think robust
demand drug overcom
competit zytiga remicad
strength pharma partial off-set
medic devic revenue saw sale
declin yoy consum
sale grew yoy orthopaed
drag medic devic quarter
expect improv
under-perform busi unit
divest octob
reuter publish stori decemb
alleg disclos fda
asbesto known caus cancer
sometim found babi powder
date back vehement
deni alleg defend
court relat case
histor enjoy lead brand
power across consum medic devic
segment combin oper profit
custom trust import
success see potenti meaning
damag import brand howev
stem recent alleg around
babi powder time contain asbesto
brand name accompani consum trust
critic success segment
view think alleg could
potenti impact futur sale everyth
babi shampoo prosthet hip
expect long-term growth improv
segment
oper profit howev becom
larger piec total sale fuel robust
drug pipelin phase clinic
trial recent fda file underway potenti
risk view includ drug price pressur
 pipelin failur potenti neg
legal judgment
target price
ep estim -- five-year
averag forward price-to-earnings see elev risk
due recent alleg cancer-caus
asbesto babi powder
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview johnson johnson rank one largest diversifi health care
firm product span across pharmaceut medic devic industri compani
also major particip global consum product busi sale account
overal sale
pharmaceut segment sale includ product therapeut area includ
immunolog neurolog oncolog pain manag urolog virolog product within
pharmaceut unit includ remicad sale billion stelara billion simponi
billion zytiga billion invega sustenna billion imbruvica billion xarelto
billion howev note best sell drug remicad lost patent protect januari
 appeal rule remicad patent invalid think result lower
remicad sale howev biosimilar remicad name inflectra approv
interchang product result think physician continu prefer prescrib
medic devic diagnost segment sale sell wide rang product
includ ethicon wound care surgic sport medicin women health care product cordi
orthopaed joint reconstruct spinal product vistakon dispos contact lens sold
ortho clinic diagnost profession diagnost product carlyl group billion
largest acquisit medic devic segment billion acquisit synth inc
consum segment sale primarili sell person care product includ
nonprescript drug adult skin hair care product babi care product oral care product first aid
product women health product nutrit product major brand includ band-aid brand
adhes bandag imodium a-d anti-diarrh johnson babi line product neutrogena skin
hair care product tylenol pain reliev
corpor strategi johnson johnson oper compani sell product
across globe despit size highli innov view seek maintain leadership
posit aggress fund new product develop spend total billion
repres sale -- billion sale may
drug late-stag develop seven phase trial fda review new recent
launch includ prezista hiv xaralto acut coronari syndrom invega schizophrenia zytiga
prostat cancer invokana type diabet imbruciva leukemia novemb fda
approv olysio treatment chronic hepat may reiter goal new
blockbust drug line extens million
annual sale blockbust drug drug gener billion annual sale
excit new therapi includ new treatment diabet cancer immun disord infecti diseas
neuropath disord
although intern growth key object compani also pursu strateg acquisit
januari acquir acclar firm work new devic treat ear nose throat
condit decemb acquisit consum health care busi ad lead
brand listerin nicorett lubriderm visin neosporin sudaf zantac benadryl
mid-jun acquir synth billion cash stock swiss maker skelet
fixat implant orthoped product synth earn million sale billion
although regul requir divest trauma busi complet deal still think
deal significantli enhanc global reach innov orthoped provid import
oper synergi think effect fund entir acquisit via oversea domicil
cash stock portion financ indirectli oversea cash
import acquisit recent year includ crucel dutch maker vaccin micru
endovascular maker devic treat stroke cougar biotechnolog firm engag
anti-cancer drug mentor corp supplier aesthet product maker
biosurg immunotherapi product conor medsystem produc cobalt chromium
coronari stent incorpor innov drug deliveri technolog juli acquir vogu
llc privately-held develop manufactur hair care person care
product billion june acquir billion retain
actelion market drug mainli treat hypertens late stage compound actelion discoveri
stage oper spun new compani own option acquir
financi trend sale grown billion billion repres
compound annual growth rate adjust ep grown
aid stock buyback repres compound annual growth rate
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc decemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next month posit view
reflect strong novel drug approv activ
see fda posit
brand drug maker repres
lion share sub-industri market
cap view temper expect
continu pressur gener drug price
neg gener drug maker lower
growth overal prescript volum
far year-over-year increas
brand drug price per prescript
around accord iqvia estim
aid strong novel drug approv activ
fda particularli weak year
novel drug approv number
rebound pace
strong growth well approv alreadi
made octob expect strong
pace novel drug approv brand drug
price inflat continu next year
aid estim approxim
year-over-year growth brand pharma
spend year end june
side coin
outlook gener drug price mostli
neg growth gener drug price
averag around neg far
dont expect major near-term
revers trend toward posit price
growth think deflationari trend
mostli driven robust gener drug
approv activ fda custom
consolid rather polit
total gener drug approv hit record
grow year-over-year
increas competit exist gener
view bring price pace
gener approv seem moder
howev approv
august versu
expect moder
deflat howev bring full-on
gener inflat due view
purchas joint ventur
three major drug distributor three largest
 retail pharmaci limit gener maker
abil rais drug price environ
joint ventur account
gener sale estim includ
cardin
walgreen
beyond drug price think prescript
volum growth fall
next year strong gain health insur
growth think
gain harder come
next year unemploy near
all-tim low remov tailwind
prescript volum growth go forward
view assum slower growth
number peopl enrol health insur
plan gener mean slower growth
use total enrol figur eight
largest health insur proxi
estim number individu
famili health insur grew
growth slow
coincid roughli growth
prescript volum far versu
accord iqvia estim
expect slow next year
increas versu rise
composit index year-to-d
octob
rise composit index
base index
five-year market price perform dec
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep estim faster growth ep vs in-lin
estim sale fx benefit rose
growth forecast cost rose higher expect growth
broad-bas domest sale intern sale fx
benefit consum sale rose pharmaceut sale aid
contribut actelion acquisit rose medic devic
sale rose encourag stabil medic devic
robust pharmaceut sale driven increas oncolog sale
strong uptak darzalex imbruvica zytiga note sale remicad fell
due higher discount rebat amid biosimilar competit
see continu weak throughout also announc plan increas
 spend due benefit tax legisl /jeffrey loo cfa
et cfra reiter buy opinion share johnson
johnson rais target
peer ep estim set
ep vs in-lin estim sale aid
acquisit rose robust pharmaceut sale
medic devic rose consum product encourag
robust pharmaceut sale oncolog immunolog infecti
diseas rebound medic devic see continu
guid sale ep
et cfra keep buy opinion share johnson johnson
rais target slightli
peer forward ep estim rais
ep estim ep vs
ahead estim sale aid recent actelion
acquisit rose organ growth pharma rose
consum rose devic aid abbott optic deal rose nda
submit apalutamid treat prostat cancer seek
approv sirukumab discontinu develop talacotuzumab /jeffrey
analyst research note compani news
pm et cfra lower opinion johnson johnson share hold
buy drop target
ep estim -- five-year averag forward price-to-earnings expect
neg impact recent alleg cancer-caus asbesto certain
product maintain ep estim lower
report surfac today alleg
disclos fda asbesto sometim found babi powder
ingredi date back vehement deni either
way expect signific damag unfold valuabl brand name
consum product medic devic built decad
consum medic devic segment gener profit brand
name accompani consum trust critic success see
today news potenti impact sale everyth babi shampoo
prosthet hip given elev risk longer feel share
attract recent price /colin scarola
lower target peer
averag ep estim view exist drug portfolio
pipelin posit ep vs slightli forecast
lower ep estim slower growth
medic devic segment initi ep estim modest
sale growth quarter yoy led pharma segment
increas oncolog group particularli strong perform within pharma
grow sale yoy total expect pharma continu
drive growth come year especi stelara imbruvica
darzalex increas sale yoy improv
margin mix think robust demand drug overcom potenti
gener competit zytiga total sale next year slower growth
medic devic consum segment grew sale yoy
et cfra keep buy opinion share johnson johnson
keep target slightli peer
forward ep estim view pipelin
posit see continu robust drug sale adjust ep vs
ahead view rais ep estim
sale includ fx benefit rose pharmaceut
medic devic consum product sale rose
world-wide fell partli declin babi
care segment due retail stock reduct discount anticip
babi care product relaunch acquisit actelion contribut
pharmaceut sale growth pharma sale driven rise
stelara sale rise invega sustenna robust rise
oncolog segment howev expect remicad sale fell due
biosimilar competit reiter plan file launch new
blockbust drug /jeffrey loo cfa
juri st loui missouri rule
asbestos-ovarian cancer link relat babi powder juri award
billion women claim develop ovarian cancer use
babi powder shower-to-show anoth talc-bas product
allegedli contamin asbesto deni babi powder
contamin asbesto appeal rule although see
case lead numer addit case relat asbesto babi powder
link believ mani year case reach final
conclus talc/babi powder lawsuit file
sever result juri decis see
overhang share howev compani success appeal
abl overturn rule /jeffrey loo cfa
et cfra keep buy opinion share johnson johnson
keep target peer
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
